secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001048477-22-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin reports record Q2 revenues of $534M; raises FY2022 guidance on Voxzogo growth
--------------------------------------------------------------------------------

- Total revenues $533.8M (+6% YoY); GAAP net income $27.7M vs $12.9M in Q2 2021.
- Voxzogo contributed $34.4M (first full quarter of U.S./EU sales); 446 children treated globally as of June 30.
- FY2022 total revenue guidance raised to $2.06-2.16B; Voxzogo net product revenue guidance raised to $130-160M.
- Expects EC approval of Roctavian for hemophilia A in Q3; BLA resubmission in U.S. planned for September 2022.
- Kuvan revenues declined 27% YoY to $57.6M due to generic competition; total revenues growth excluding Kuvan was 13% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847722000025/0001048477-22-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847722000025/bmrn-20220803.htm
  HTML page:      https://secwatch.observer/filing/0001048477-22-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer